Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Non-Current Liabilities (2016 - 2026)

Catalyst Pharmaceuticals filings provide 15 years of Other Non-Current Liabilities readings, the most recent being $280000.0 for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 8.11% to $280000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $280000.0, a 8.11% increase, with the full-year FY2025 number at $209000.0, down 33.65% from a year prior.
  • Other Non-Current Liabilities hit $280000.0 in Q1 2026 for Catalyst Pharmaceuticals, up from $209000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $14.7 million in Q3 2022 to a low of $161000.0 in Q3 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $2.6 million (2024), compared with a mean of $4.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 94.22% in 2025 and later grew 8.11% in 2026.
  • Catalyst Pharmaceuticals' Other Non-Current Liabilities stood at $14.1 million in 2022, then crashed by 78.8% to $3.0 million in 2023, then plummeted by 89.44% to $315000.0 in 2024, then tumbled by 33.65% to $209000.0 in 2025, then soared by 33.97% to $280000.0 in 2026.
  • The last three reported values for Other Non-Current Liabilities were $280000.0 (Q1 2026), $209000.0 (Q4 2025), and $161000.0 (Q3 2025) per Business Quant data.